Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, In-Wha | - |
dc.contributor.author | Moon, Yoo Jin | - |
dc.contributor.author | Ji, Eunhee | - |
dc.contributor.author | Kim, Kyung Im | - |
dc.contributor.author | Han, Nayoung | - |
dc.contributor.author | Kim, Sung Ju | - |
dc.contributor.author | Shin, Wan Gyoon | - |
dc.contributor.author | Ha, Jongwon | - |
dc.contributor.author | Yoon, Jeong-Hyun | - |
dc.contributor.author | Lee, Hye Suk | - |
dc.contributor.author | Oh, Jung Mi | - |
dc.date.accessioned | 2021-09-06T20:16:17Z | - |
dc.date.available | 2021-09-06T20:16:17Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2012-05 | - |
dc.identifier.issn | 0031-6970 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/108506 | - |
dc.description.abstract | The purpose of this study was to characterize the effects of clinical and genetic variables on the pharmacokinetics and complications of tacrolimus during the first year after kidney transplantation. One hundred and thirty-two Korean kidney recipients who received tacrolimus were genotyped for ABCB1 (exons 12, 21, and 26) and CYP3A5 (intron 3). Tacrolimus trough levels, dose, or dose-adjusted trough levels and complications were compared among patients during the early stage (3, 7, 14, 30, and 90 days) and up to 1 year according to the genotypes. A donor source-adjusted linear mixed model with multilevel analysis adjusting for age, body weight, hematocrit, and serum creatinine showed that CYP3A5 genotype is associated with dose-adjusted level of tacrolimus (p < 0.001). The influence of ABCB1 polymorphisms on the pharmacokinetics or complications of tacrolimus was less certain in our study. The incidence of acute rejections was significantly higher in recipients of cadaveric donor kidney (p < 0.05). A generalized estimating equation model analysis showed that alopecia and hyperlipidemia were associated with dose-adjusted level of tacrolimus (p < 0.001). Genotype of CYP3A5 variants along with significant clinical covariates may be useful in individualizing tacrolimus therapy in kidney transplantation patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER HEIDELBERG | - |
dc.subject | ACUTE REJECTION | - |
dc.subject | RENAL-TRANSPLANTATION | - |
dc.subject | ABCB1 POLYMORPHISMS | - |
dc.subject | DOSE REQUIREMENTS | - |
dc.subject | SERUM CREATININE | - |
dc.subject | CYP3A5 | - |
dc.subject | PHARMACOKINETICS | - |
dc.subject | CYCLOSPORINE | - |
dc.subject | BLOOD | - |
dc.subject | FK506 | - |
dc.title | Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Kyung Im | - |
dc.identifier.doi | 10.1007/s00228-011-1182-5 | - |
dc.identifier.scopusid | 2-s2.0-84864281590 | - |
dc.identifier.wosid | 000303452800022 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, v.68, no.5, pp.657 - 669 | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | - |
dc.citation.title | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | - |
dc.citation.volume | 68 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 657 | - |
dc.citation.endPage | 669 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ACUTE REJECTION | - |
dc.subject.keywordPlus | RENAL-TRANSPLANTATION | - |
dc.subject.keywordPlus | ABCB1 POLYMORPHISMS | - |
dc.subject.keywordPlus | DOSE REQUIREMENTS | - |
dc.subject.keywordPlus | SERUM CREATININE | - |
dc.subject.keywordPlus | CYP3A5 | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | CYCLOSPORINE | - |
dc.subject.keywordPlus | BLOOD | - |
dc.subject.keywordPlus | FK506 | - |
dc.subject.keywordAuthor | Tacrolimus | - |
dc.subject.keywordAuthor | Polymorphism | - |
dc.subject.keywordAuthor | Pharmacogenetics | - |
dc.subject.keywordAuthor | Kidney | - |
dc.subject.keywordAuthor | Transplantation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.